Article
Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Journal of hepatology - 1 Jun 2017
Prenner Stacey B, VanWagner Lisa B, Flamm Steven L, Salem Riad, Lewandowski Robert J, Kulik Laura
Abstract excerpt
BACKGROUND & AIMS: The approval of all-oral direct-acting antiviral (DAA) regimens for the treatment of hepatitis C virus (HCV) has led to the expansion of therapy to include patients with cirrhosis who have hepatocellular carcinoma (HCC). Data on the use of DAAs in HCV+ patients with HCC is limited. The aim of this study was to assess the efficacy of all-oral-DAA regimens in HCV+ cirrhotic patients who have or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
